Top Market Shifts Transforming the Gastroesophageal Reflux Disease Therapeutics Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Gastroesophageal Reflux Disease Therapeutics Market Through 2025?
The market size of therapeutics for gastroesophageal reflux disease has seen a consistent progression in the past few years. This market is forecasted to expand from $5.93 billion in 2024 to $6.08 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 2.5%. Factors such as the modification of lifestyle and food practices, the growing population of the elderly, enhanced recognition and diagnostic measures, the prevalence of stress-filled lifestyles, and upswing in obesity rates are contributing to the growth observed in the historical period.

What's the Projected Size of the Global Gastroesophageal Reflux Disease Therapeutics Market by 2029?
The market for therapeutics for gastroesophageal reflux disease is predicted to experience significant expansion in the coming years. By 2029, it is anticipated to be worth $7.74 billion, with a compound annual growth rate (CAGR) of 6.2%. The forecasted growth for this period is associated with increased demand for new treatments, a rising older population, the advent of personalised medicine strategies, a focus on non-drug interventions, as well as the emergence of biologics and innovative therapies. Major trends expected in this period involve alternative therapies and mind-body practices, enhanced gut health research, the introduction of patient-focused care models, targeted promotion for gerd awareness, and the integration of digital health tools.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Top Growth Drivers in the Gastroesophageal Reflux Disease Therapeutics Industry: What's Accelerating the Market?
The gastroesophageal reflux disease therapeutics market may witness significant growth triggered by the increasing prevalence of gastroesophageal reflux disease. This chronic ailment denotes the stomach acid's backward flow into the esophagus, subsequently leading to symptoms such as heartburn, regurgitation, and potential complications. The therapeutics designed for treating gastroesophageal reflux disease (GERD) work by neutralizing the stomach's pH balance, reducing inflammation, and enhancing the functioning of the esophagus. As per a WebMed article published in September 2022, more than 60 million American adults experience heartburn at least once per month, with over 15 million of them suffering daily. Additionally, the National Library of Medicine, a federal medical library based in the US, stated in July 2022 that GERD is among the most frequently diagnosed digestive disorders in the country, with a prevalence rate of 20%. This leads not only to significant economic stress due to direct and indirect healthcare costs but it also negatively affects the patient's quality of life. Thus, the high incidence rate of GERD is anticipated to bolster the market growth of therapeutics for gastroesophageal reflux disease.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp

What Are the Key Trends Driving Gastroesophageal Reflux Disease Therapeutics Market Growth?
The gastroesophageal reflux disease therapeutics market is increasingly being characterized by product innovations. To remain competitive, leading companies in this field are focusing on the development of inventive medications. An example of this trend was set by Phathom Pharmaceuticals, an American biopharmaceutical firm, which launched VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, in November 2023. The medication, approved for the treatment and maintenance of all grades of erosive esophagitis and the relief of heartburn linked with both erosive and non-erosive GERD, produced notable results in clinical trials. Specifically, it achieved a 93% healing rate in patients who underwent the 20 mg dosage, which is higher than the 85% rate for the conventional proton pump inhibitor (PPI) lansoprazole.

What Are the Main Segments in the Gastroesophageal Reflux Disease Therapeutics Market?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented -

1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
4) By Application: Crohn's Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp

Which Top Companies are Driving Growth in the Gastroesophageal Reflux Disease Therapeutics Market?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited

Which Regions Will Dominate the Gastroesophageal Reflux Disease Therapeutics Market Through 2029?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12058

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.